Sinopharm Group (01099) released principal unaudited accounting data and financial indicators for its subsidiary SINOPHARM (CNCM LTD) (600511) for the third quarter of 2025. According to the announcement, SINOPHARM (CNCM LTD) recorded RMB13.75 billion in revenue for the reporting period, representing a 3.58% increase compared to the same period last year. From the beginning of the year to the end of the reporting period, cumulative revenue reached RMB39.38 billion, up 3.56% year on year.

Net profit attributable to shareholders of SINOPHARM (CNCM LTD) in the third quarter totaled RMB543.72 million, representing a 13.10% increase compared to the same period last year. Cumulative net profit for the first nine months amounted to RMB1.49 billion, reflecting a 0.74% increase year on year. After deducting non-recurring gains and losses, SINOPHARM (CNCM LTD)’s net profit stood at RMB538.64 million in the third quarter, up 10.84% compared to the same period last year, while its total for the first nine months was RMB1.47 billion, registering a slight year-on-year decrease of 1.27%.

As of 30 September 2025, SINOPHARM (CNCM LTD) reported total assets of RMB35.13 billion, up 0.56% from the end of the previous year. Equity attributable to shareholders of the listed company reached RMB18.04 billion, an increase of 5.34% over the same period. Basic and diluted earnings per share for the third quarter were RMB0.7206, and both were up 13.10% from a year earlier. Over the first nine months, basic and diluted earnings per share increased 0.74% to RMB1.9778, while the weighted average return on net assets for the same period stood at 8.50%.